Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB | Zendy

Christopher Vinnard | Zendy; Shruthi Ravimohan | Zendy; Neo Tamuhla | Zendy; Jotam G. Pasipanodya | Zendy; Shashikant Srivastava | Zendy; Chawangwa Modongo | Zendy; Nicola M. Zetola | Zendy; Drew Weissman | Zendy; Tawanda Gumbo | Zendy; Gregory P. Bisson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB

Author(s) -

Christopher Vinnard,

Shruthi Ravimohan,

Neo Tamuhla,

Jotam G. Pasipanodya,

Shashikant Srivastava,

Chawangwa Modongo,

Nicola M. Zetola,

Drew Weissman,

Tawanda Gumbo,

Gregory P. Bisson

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx111

Subject(s) - bioavailability , rifampicin , human immunodeficiency virus (hiv) , medicine , tuberculosis , antibacterial agent , antibiotics , microbiology and biotechnology , virology , pharmacology , biology , pathology

Rifampicin is the key drug responsible for sterilizing activities in the first-line TB treatment regimen. Damage to the gut during acute and chronic HIV infection may inhibit drug absorptive capacity. We sought to test the hypothesis that markers of intestinal damage, bacterial translocation and systemic immune activation would relate to rifampicin bioavailability among HIV/TB patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research